Sionna seeks $156M IPO for cystic fibrosis studies

The Top Line Podcast: Don’t miss out on the newest episode. Listen now.

 

Featured

Sanofi-backed AdvanCell secures $112M series C to fund targeted alpha radiopharma trial

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial.
 

Top Stories

Irish biotech's inhaled drug reduces depression in phase 2 trial

Irish biotech GH Research has said the phase 2 win for its inhaled depression drug has “paved the way for future commercial success.”

Sionna eyes up $156M IPO to fund cystic fibrosis trials

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into phase 2.

Affibody regains autoimmune asset, claims ex-partner Acelyrin unable 'to fully capitalize' on potential

Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, completing a retreat from its former lead candidate that began with the axing of development in two diseases in August. The news led Affibody to claim its former partner “has not been able to fully capitalize” on the asset’s potential.

Fierce Biotech Layoff Tracker 2025: Cargo halves staff; I-Mab trims team by 27%

As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.

Trump tariffs threaten US drug supplies and risk higher prices, trade groups warn

With President Donald Trump’s tariffs now in place, industry groups are warning that the move could hamstring U.S. pharmaceutical supplies and productivity.

Top Republican airs concerns about RFK Jr.'s 'bully pulpit' and vaccine hesitancy

Sen. Bill Cassidy, chair of the Senate HELP Committee, and ranking member Bernie Sanders were aligned on their concerns about RFK Jr.'s approach to vaccines. With a vote on RFK Jr.’s nomination to take place in the Senate Finance Committee next week, Cassidy, who also sits on that committee, said he’s going to have to use the weekend to make up his mind.

Sugar from soil bacteria restores pigment in mice with vitiligo: study

A sugar produced by soil bacteria may be able to stop the loss of skin pigment caused by vitiligo. A new study found that injecting the molecule into mice with the autoimmune disease slowed the rate of the rodents’ pigment loss and boosted the amount of pigment-protecting T cells.

Pfizer's Braftovi combo on track for full approval in win for FDA's Project FrontRunner

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in positive trial results that could set it up for a full approval.

Trump administration indefinitely suspends meetings of HHS' health IT advisory committee

The Trump administration indefinitely canceled meetings of the HITAC, an advisory panel established by the 21st Century Cures Act that helps the federal government establish rules and standards for the use of healthcare data and technologies.
 
Fierce podcasts

Don’t miss an episode

What to expect from the biotech IPO market in 2025

This week on “The Top Line,” we zoom in on a Fierce JPM Week panel of industry experts discussing what it will take for biotechs to pull off a successful IPO in 2025.
 

Resources

Whitepaper

The Oncology Market: 2024 Year in Review

This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future.

 

Upcoming Fierce Events

29-1
Apr-May
San Diego, CA
7-9
May
Free Virtual Event
8-11
Sep
Philadelphia, PA
7-9
Oct
Boston, MA

View all events